Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Xaar revenue rises, adjusted losses widen slightly

(Sharecast News) - Xaar reported higher first-half revenue on Tuesday, driven by strong growth in its printhead business, as it said it remained on track to meet full-year expectations despite tariff-related headwinds affecting part of the group. Revenue for the six months ended 30 June rose 7% year-on-year to £27.2m, with printhead sales up 20% to £19.9m, accounting for 73% of the total.

Growth was led by a jump in jewellery wax revenue to £3.3m from £0.6m a year earlier, while printhead operating margin improved 70 basis points to 10.4%.

Engineered print systems (EPS) revenue fell 16% to £6.3m, reflecting delayed capital investment due to tariff uncertainty, though Xaar said the order pipeline is now recovering.

Gross margin slipped slightly to 36.5%, while adjusted EBITDA declined 15% to £0.76m.

The London-listed firm said its adjusted loss before tax widened marginally to £0.7m, as its statutory loss came in at £3.1m, compared with £2.6m in the first half of 2024, with net cash down to £5.1m following investment in equipment and development.

"The start of 2025 has been encouraging with the swift progress made in the jewellery wax market, reflecting the disruptive impact our technology will have in our target markets once OEM products have been launched," said chief executive John Mills.

"Opportunities in EV battery coating, automotive coating and desktop 3D are setting the Group up for sustainable medium-term growth with key developments within each market progressing as planned."

Xaar reiterated that revenue would be weighted towards the second half, with further growth in printhead sales expected, while EPS performance would remain affected by tariffs until the pipeline rebuilt.

The company said medium-term prospects were supported by maturing recent product launches and upcoming developments, with management confident of meeting current market expectations.

At 1021 BST, Xaar shares were down 4.18% at 114.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.